- +91 8471002000
- Messenger
Immunotherapy
Pembrolizumab
Pembrolizumab Injection
Injection
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Pembrolizumab Dosage: 200mg IV infusion every 3 weeks (Q3W)
Pembrolizumab is an approved therapeutic agent for numerous cancer types including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin's lymphoma, urothelial carcinoma, gastric cancer, esophageal cancer, and tumors with microsatellite instability or impaired mismatch repair. The drug functions by enhancing the immune system's capacity to combat tumor development.
Pembrolizumab, a groundbreaking immunotherapy treatment, empowers a patient's immune system to detect and eliminate cancerous cells. By blocking the cancer cells' exploitation of the PD-1 protein, which helps them evade immune defenses, this therapy unleashes the immune system's full potential. Remarkably versatile, pembrolizumab has proven effective against various cancer types, ushering in a new era of personalized cancer care and treatment options.
Pembrolizumab resistance arises when tumor cells modify their structural composition to evade immune checkpoint inhibition, resulting in compromised T-cell interaction, reduced presentation of cancer antigens, and heightened obstructive elements. This impedes pembrolizumab's efficacy, lowering its battling strength against cancerous growths.
Pembrolizumab injection usage can result in diverse adverse reactions, such as weariness, continuous coughing, feelings of nausea, and skin irritation. In certain instances, it might provoke severe consequences like self-directed attacks on healthy organs, lung inflammation, liver-related issues, or serious infusion-related complications. Continuous monitoring is essential for timely detection and management of these concerns.
Pembrolizumab can be effectively combined with multiple treatment drugs, depending on the specific cancer type. In non-squamous non-small cell lung cancer (NSCLC) cases, a common mixture includes pemetrexed along with platinum-derived chemotherapy medications such as cisplatin or carboplatin, together with pembrolizumab. Furthermore, the FDA has authorized the concurrent use of pembrolizumab and axitinib for addressing advanced renal cell carcinoma (RCC). It is essential to consult a healthcare professional for customized treatment options.
Avg cost of Pembrolizumab Injection: ₹72,500 in India. The above price is specific for Chitradurga, Karnataka, India
WhatsApp us